Company Active LTD

Company profile

Gentronix Limited

Gentronix - Experts in Predictive Toxicology

Gentronix provides services to help expedite the discovery, early-stage development and safe manufacture of novel drugs.

CRN
03810162
Founded
1999
Age
26

Overview

Legal name
GENTRONIX LIMITED
Region
North West England
Registered address
BLOCK 23 MERESIDE
ALDERLEY PARK
ALDERLEY EDGE
CHESHIRE
ENGLAND
SK10 4TG
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Gentronix Limited
CRN 03810162
2
Direct and ultimate controller Active LTD
Scantox UK Limited
CRN 15890541

Latest accounts

Financial period: 1 Sep 2023 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
£1,663,066
Employees
64

Company events

Reference milestones and recent Companies House filing stream events.

20 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

29 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

15 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

24 Sep
2024

Mortgage Create With Deed With Charge Number Charge Creation Date

Mortgage

MR01 | Transaction MzQzNzAzMTA1OWFkaXF6a2N4

Published 28 Sep 2024 10:25

20 Sep
2024

Resolution

Resolution

RESOLUTIONS | Transaction WURCS0JTNE9hZGlxemtjeA | Paper/PDF filed

Published 24 Sep 2024 07:05

16 Sep
2024

Cessation Of A Person With Significant Control

Persons-with-significant-control

PSC07 | Transaction MzQzNTk4MTA0NGFkaXF6a2N4

Published 16 Sep 2024 09:37

16 Sep
2024

Cessation Of A Person With Significant Control

Persons-with-significant-control

PSC07 | Transaction MzQzNTk4MDkyOWFkaXF6a2N4

Published 16 Sep 2024 09:36

16 Sep
2024

Notification Of A Person With Significant Control

Persons-with-significant-control

PSC02 | Transaction MzQzNTk3NTA1NmFkaXF6a2N4

Published 16 Sep 2024 08:58

16 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNTk3MzY3NWFkaXF6a2N4

Published 16 Sep 2024 08:50

16 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNTk3MzcwM2FkaXF6a2N4

Published 16 Sep 2024 08:50

16 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNTk3MzY5NGFkaXF6a2N4

Published 16 Sep 2024 08:50

16 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNTk3MzY2MGFkaXF6a2N4

Published 16 Sep 2024 08:49

16 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNTk3MzUyMGFkaXF6a2N4

Published 16 Sep 2024 08:48

16 Sep
2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQzNTk3MzMxN2FkaXF6a2N4

Published 16 Sep 2024 08:48

16 Sep
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzNTkzNzk2NGFkaXF6a2N4

Published 16 Sep 2024 08:09

04 Sep
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzNDQ5NTAxNGFkaXF6a2N4

Published 04 Sep 2024 13:23

27 Aug
2024

Resolution

Resolution

RESOLUTIONS | Transaction WURBNTBaM0NhZGlxemtjeA | Paper/PDF filed

Published 28 Aug 2024 07:14

23 Aug
2024

Memorandum Articles

Incorporation

MA | Transaction MzQzMjYxMzA3NmFkaXF6a2N4 | Paper/PDF filed

Published 24 Aug 2024 07:02

15 Jul
1999

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2013
Funded years
2013, 2014
Age at first award
13 years

Projects

2014 Feasibility Studies Lead participant

Reducing animal use through more accurate in vitro mutagenicity testing

1 Jul 2014 to 31 Jul 2014

Awarded
£0
Total cost £0

Continued innovation by the diverse chemical sectors is expected to provide new, better, and more effective medicines, herbicides, pesticides and consumer products. The public expects these to be safe as well as effective. Cancer risk is perhaps the most concerning. The most potent carcinogens are mutagens: compounds that alter the DNA sequences in our ce...

2013 Feasibility Studies Lead participant

Assessment of the feasibility of developing an in vitro screen for epigenetic mutagens

1 Feb 2013 to 30 Apr 2014

Awarded
£147,335
Total cost £196,447

The human genome is complex and well protected by an array of systems that sense damage, and initiate repair. When damage is overwhelming, cells are usually forced into suicide to minimise the generation of viable mutant cells that might develop into tumours. Direct DNA damage is not the only threat to the genome. Tissues such as liver, kidney, muscle etc...

Product types

Feasibility Studies